Aurinia Pharmaceuticals Inc. (AUPH)
NASDAQ: AUPH · Real-Time Price · USD
15.61
0.00 (0.00%)
Apr 2, 2026, 4:00 PM EDT - Market closed
Aurinia Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts that cover Aurinia Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $17.25, which forecasts a 10.51% increase in the stock price over the next year. The lowest target is $15 and the highest is $21.
Price Target: $17.25 (+10.51%)
Analyst Consensus: Buy
* Price targets were last updated on Dec 3, 2025.
Analyst Ratings
The average analyst rating for Aurinia Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $15 → $16 | Buy → Hold | Downgrades | $15 → $16 | +2.50% | Dec 3, 2025 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $10 → $21 | Hold → Strong Buy | Upgrades | $10 → $21 | +34.53% | Nov 7, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $9 → $15 | Buy → Hold | Downgrades | $9 → $15 | -3.91% | Nov 5, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $8 → $9 | Buy | Maintains | $8 → $9 | -42.34% | Aug 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $17 | Strong Buy | Initiates | $17 | +8.90% | Jul 30, 2025 |
Financial Forecast
Revenue This Year
329.85M
from 283.06M
Increased by 16.53%
Revenue Next Year
383.42M
from 329.85M
Increased by 16.24%
EPS This Year
0.82
from 2.07
Decreased by -60.19%
EPS Next Year
1.00
from 0.82
Increased by 20.98%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 360.7M | 478.2M | |||
| Avg | 329.9M | 383.4M | |||
| Low | 296.5M | 342.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 27.4% | 45.0% | |||
| Avg | 16.5% | 16.2% | |||
| Low | 4.7% | 3.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.98 | 1.65 | |||
| Avg | 0.82 | 1.00 | |||
| Low | 0.63 | 0.44 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -52.8% | 100.0% | |||
| Avg | -60.2% | 21.0% | |||
| Low | -69.7% | -46.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.